Journey Medical Corp. (DERM)

A. Company Overview

Journey Medical Corporation, founded in October 2014, operates as a commercial-stage pharmaceutical company focused specifically on dermatological conditions. Headquartered in Scottsdale, Arizona, Journey Medical is primarily engaged in the development and commercialization of a range of pharmaceutical products aimed at improving patient quality of life, while also enabling healthcare professionals to provide effective treatments. The company maintains a portfolio that includes seven branded prescription drugs and two authorized generic drugs that are marketed within the United States. It is also recognized as a majority-owned subsidiary of Fortress Biotech, Inc.

The management team within Journey Medical is composed of experienced life science executives who have a proven history in product commercialization and value creation for stakeholders. The organization emphasizes acquiring rights to new products through various mechanisms, including licensing and partnerships, and seeks to fund the necessary research and development for these products before bringing them to market through an established field sales organization. Since its inception, Journey Medical has made robust investments to expand its commercial product portfolio, believing that its strong sales leadership and skilled field sales team will drive future growth.

B. 2023 Highlights and Events

Positive strides were made in 2023. On December 27, the company entered into a Credit Agreement with SWK Funding LLC, granting access to a term loan facility with an initial draw of $15 million, leaving $5 million available for future request within the next year. The term loans mature in December 2027, with quarterly interest payments beginning in February 2024.

Notably, a license agreement was established with Maruho Co., Ltd., a well-known Japanese dermatology-focused company, for the exclusive rights to develop and commercialize Qbrexza® in specified Asian markets. This agreement included a $19 million upfront payment and arrangements for ongoing royalty payments based on sales.

Additionally, Journey Medical announced favorable topline results from two Phase 3 clinical trials for DFD-29, a drug targeting papulopustular rosacea, demonstrating significant effectiveness when compared to both standard care and placebo. An NDA (New Drug Application) was submitted to the FDA, with an expected approval timeline falling in the latter half of 2024.

C. Corporate Information

Journey Medical Corporation is incorporated in Delaware. Executive operations are centralized at its Scottsdale location, focusing on both research and development as well as commercialization efforts. The internal team consists of 58 full-time employees across various domains, particularly sales, marketing, and general administration.

D. Market, Products and Relevant Disease States

The company primarily targets dermatological conditions, including but not limited to:

Primary Axillary Hyperhidrosis

Qbrexza® (glycopyrronium 2.4% cloth) is positioned as a topical treatment for excessive underarm sweating. This product was FDA-approved in June 2018 for both adult and pediatric patients starting at age nine. The total addressable market for primary axillary hyperhidrosis is considerable, with approximately 10 million individuals affected in the U.S., contributing to around 450,000 prescriptions written for such treatments in 2023.

Acne Vulgaris

Journey Medical offers multiple products for the treatment of acne, which is recognized as the most common skin condition in the U.S., impacting around 50 million individuals each year.

• Accutane® (isotretinoin) is prescribed for severe recalcitrant nodular acne, while Targadox® (doxycycline) serves as adjunctive therapy.
• Amzeeq® (4% minocycline foam) was FDA-approved in late 2019 for treating inflammatory lesions in moderate-to-severe non-nodular acne cases.

E. Anti-Fungal Treatments

Exelderm® (sulconazole nitrate) is another important product within Journey’s portfolio, indicated for various fungal skin infections such as athlete's foot and jock itch, with a significant volume of over 11 million prescriptions in 2023.

F. Itch Relief

The company also plans to introduce an Anti-Itch Product capable of providing prescription relief for pruritus and related conditions, anticipated for launch in late 2024 or early 2025.

G. Rosacea Treatments

Journey Medical's Zilxi® (1.5% minocycline foam) has been dispensed for treating inflammatory lesions of rosacea, establishing its presence in a market with significant unmet patient needs.

H. Manufacturing and Supply Chain

Journey Medical does not maintain its own manufacturing facilities; instead, the company relies on contract manufacturers that adhere to current Good Manufacturing Practices (cGMP). These relationships are critical for ongoing production and supply chain reliability, particularly as the company scales its operations and seeks to bring additional products to market.

I. Competitive Landscape

Journey Medical operates in a highly competitive dermatology sector characterized by various established pharmaceutical companies, biotechnology firms, and generic drug manufacturers. Competitors vary significantly based on product category, market segment, and therapeutic area, with notable players including Galderma, Almirall, and Novan Therapeutics among others.

The company differentiates itself through a focused portfolio that addresses specific, high-demand conditions while promoting innovation in drug delivery and formulation technology.

J. Intellectual Property

Strong patent protection is essential to Journey Medical’s strategic approach, with various products currently covered under multiple U.S. patents, ensuring the protection of proprietary technologies and formulations. Continuous efforts are made to secure intellectual property rights extending over a substantial duration to provide a competitive edge in the marketplace.